An elevated expression of serum exosomal microRNA-191,-21,-451a of pancreatic neoplasm is considered to be efficient diagnostic marker

被引:187
作者
Goto, Takuma [1 ]
Fujiya, Mikihiro [1 ]
Konishi, Hiroaki [1 ]
Sasajima, Junpei [1 ]
Fujibayashi, Shugo [1 ]
Hayashi, Akihiro [1 ]
Utsumi, Tatsuya [1 ]
Sato, Hiroki [1 ]
Iwama, Takuya [1 ]
Ijiri, Masami [1 ]
Sakatani, Aki [1 ]
Tanaka, Kazuyuki [1 ]
Nomura, Yoshiki [1 ]
Ueno, Nobuhiro [1 ]
Kashima, Shin [1 ]
Moriichi, Kentaro [1 ]
Mizukami, Yusuke [1 ]
Kohgo, Yutaka [2 ]
Okumura, Toshikatsu [1 ]
机构
[1] Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan
[2] Int Univ Hlth & Welf Hosp, Dept Gastroenterol, Nasushiobara, Japan
基金
日本学术振兴会;
关键词
Pancreatic cancer; Exosome; microRNA-21; microRNA-451a; Intraductal papillary mucinous neoplasm; Tumor marker; THERAPEUTIC TARGET; TUMOR-SUPPRESSOR; FOLLOW-UP; MICRORNA-21; CANCER; MANAGEMENT; ADENOCARCINOMA; PROLIFERATION; BIOMARKERS; INVASION;
D O I
10.1186/s12885-018-4006-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pancreatic cancer is associated with an extremely poor prognosis, so new biomarkers that can detect the initial stages are urgently needed. The significance of serum microRNA (miR) levels in pancreatic neoplasm such as pancreatic cancer and intraductal papillary mucinous neoplasm (IPMN) diagnosis remains unclear. We herein evaluated the usefulness of miRs enclosed in serum exosomes (ExmiRs) as diagnostic markers. Methods: The ExmiRs from patients with pancreatic cancer (n = 32) or IPMN (n = 29), and patients without neoplasms (controls; n = 22) were enriched using ExoQuick-TC (TM). The expression of ExmiRs was evaluated using a next-generation sequencing analysis, and the selected three miRs through this analysis were confirmed by a quantitative real-time polymerase chain reaction. Results: The expression of ExmiR-191, ExmiR-21 and ExmiR-451a was significantly up-regulated in patients with pancreatic cancer and IPMN compared to the controls (p < 0.05). A receiver operating characteristic curve analysis showed that the area under the curve and the diagnostic accuracy of ExmiRs were 5-20% superior to those of three serum bulky circulating miRs (e.g.; ExmiR-21: AUC 0.826, accuracy 80.8%. Circulating miR-21: AUC 0.653, accuracy 62.3%). In addition, high ExmiR-451a was associated with mural nodules in IPMN (p = 0.010), and high ExmiR-21 was identified as a candidate prognostic factor for the overall survival (p = 0.011, HR 4.071, median OS of high-ExmiR-21: 344 days, median OS of low-ExmiR-21: 846 days) and chemo-resistant markers (p = 0.022). Conclusions: The level of three ExmiRs can thus serve as early diagnostic and progression markers of pancreatic cancer and IPMN, and considered more useful markers than the circulating miRs (limited to these three miRs).
引用
收藏
页数:11
相关论文
共 30 条
[1]   The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal [J].
Ballehaninna, Umashankar K. ;
Chamberlain, Ronald S. .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2012, 3 (02) :105-119
[2]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[3]   microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis [J].
Frampton, Adam E. ;
Krell, Jonathan ;
Jamieson, Nigel B. ;
Gall, Tamara M. H. ;
Giovannetti, Elisa ;
Funel, Niccola ;
Prado, Mireia Mato ;
Krell, Daniel ;
Habib, Nagy A. ;
Castellano, Leandro ;
Jiao, Long R. ;
Stebbing, Justin .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (11) :1389-1404
[4]   Upregulation of miR-21 by Ras in vivo and its role in tumor growth [J].
Frezzetti, D. ;
De Menna, M. ;
Zoppoli, P. ;
Guerra, C. ;
Ferraro, A. ;
Bello, A. M. ;
De Luca, P. ;
Calabrese, C. ;
Fusco, A. ;
Ceccarelli, M. ;
Zollo, M. ;
Barbacid, M. ;
Di Lauro, R. ;
De Vita, G. .
ONCOGENE, 2011, 30 (03) :275-286
[5]   The Majority of MicroRNAs Detectable in Serum and Saliva Is Concentrated in Exosomes [J].
Gallo, Alessia ;
Tandon, Mayank ;
Alevizos, Ilias ;
Illei, Gabor G. .
PLOS ONE, 2012, 7 (03)
[6]   MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity [J].
Giovannetti, Elisa ;
Funel, Niccola ;
Peters, Godefridus J. ;
Del Chiaro, Marco ;
Erozenci, Leyla A. ;
Vasile, Enrico ;
Leon, Leticia G. ;
Pollina, Luca E. ;
Groen, Annemieke ;
Falcone, Alfredo ;
Danesi, Romano ;
Campani, Daniela ;
Verheul, Henk M. ;
Boggi, Ugo .
CANCER RESEARCH, 2010, 70 (11) :4528-4538
[7]   MicroRNA-21 Regulates the Proliferation and Invasion in Esophageal Squamous Cell Carcinoma [J].
Hiyoshi, Yukiharu ;
Kamohara, Hidenobu ;
Karashima, Ryuichi ;
Sato, Nobutaka ;
Imamura, Yu ;
Nagai, Youhei ;
Yoshida, Naoya ;
Toyama, Eiichiro ;
Hayashi, Naoko ;
Watanabe, Masayuki ;
Baba, Hideo .
CLINICAL CANCER RESEARCH, 2009, 15 (06) :1915-1922
[8]   MicroRNA-21: a therapeutic target for reversing drug resistance in cancer [J].
Hong, Liu ;
Han, Yu ;
Zhang, Yujie ;
Zhang, Hongwei ;
Zhao, Qingchuan ;
Wu, Kaichun ;
Fan, Daiming .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (09) :1073-1080
[9]   MicroRNA-21 in Pancreatic Ductal Adenocarcinoma Tumor-Associated Fibroblasts Promotes Metastasis [J].
Kadera, Brian E. ;
Li, Luyi ;
Toste, Paul A. ;
Wu, Nanping ;
Adams, Curtis ;
Dawson, David W. ;
Donahue, Timothy R. .
PLOS ONE, 2013, 8 (08)
[10]   Differential Stability of Cell-Free Circulating microRNAs: Implications for Their Utilization as Biomarkers [J].
Koeberle, Verena ;
Pleli, Thomas ;
Schmithals, Christian ;
Alonso, Eduardo Augusto ;
Haupenthal, Joerg ;
Boenig, Halvard ;
Peveling-Oberhag, Jan ;
Biondi, Ricardo M. ;
Zeuzem, Stefan ;
Kronenberger, Bernd ;
Waidmann, Oliver ;
Piiper, Albrecht .
PLOS ONE, 2013, 8 (09)